Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Haloperidol-stomach lesions attenuation by pentadecapeptide BPC 157, omeprazole, bromocriptine, but not atropine, lansoprazole, pantoprazole, ranitidine, cimetidine and misoprostol in mice
Autore:
Bilic, I; Zoricic, I; Anic, T; Separovic, J; Stancic-Rokotov, D; Mikus, D; Buljat, G; Ivankovic, D; Aralica, G; Prkacin, I; Perovic, D; Mise, S; Rotkvic, I; Petek, M; Rucman, R; Seiwerth, S; Sikiric, P;
Indirizzi:
Univ Zagreb, Fac Med, Dept Pharmacol, Zagreb 10000, Croatia Univ Zagreb Zagreb Croatia 10000 , Dept Pharmacol, Zagreb 10000, Croatia
Titolo Testata:
LIFE SCIENCES
fascicolo: 16, volume: 68, anno: 2001,
pagine: 1905 - 1912
SICI:
0024-3205(20010309)68:16<1905:HLABPB>2.0.ZU;2-8
Fonte:
ISI
Lingua:
ENG
Soggetto:
DOPAMINE AGONISTS; GASTRIC-ULCERS; RATS; ANTAGONISTS; INDOMETHACIN; DISEASE; MODEL;
Keywords:
haloperidol stomach lesions; mice; domperidone; indomethacin; pentadecapeptide BPC 157; bromocriptine; omeperazole; atropine; pirenzepine; lansoprazole; pantroprazole; misoprostol; cimetidine; ranitidine; central/peripheral dopamine; prostaglandins;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
17
Recensione:
Indirizzi per estratti:
Indirizzo: Sikiric, P Univ Zagreb, Fac Med, Dept Pharmacol, Salata 11,POB 916, Zagreb10000, Croatia Univ Zagreb Salata 11,POB 916 Zagreb Croatia 10000 00, Croatia
Citazione:
I. Bilic et al., "Haloperidol-stomach lesions attenuation by pentadecapeptide BPC 157, omeprazole, bromocriptine, but not atropine, lansoprazole, pantoprazole, ranitidine, cimetidine and misoprostol in mice", LIFE SCI, 68(16), 2001, pp. 1905-1912

Abstract

The focus was on haloperidol (central dopamine antagonist)-stomach lesion,a longly described suitable counterpart of dopamine blocker cysteamine-duodenal lesion. In this, the contribution of blockade of central/peripheral dopamine receptors and prostaglandins synthesis, along with influence of antiulcer agents was evaluated in mice. Male NMRI Hannnover mice were sacrificed 24 h after haloperidol (25 mg/kg b.w. i.p., given alone or with saline (haloperidol+saline) (i) or in combination (ii,iii)). Supporting central dopamine predominance for haloperidol stomach lesion induction, coadministration of peripheral dopamine receptor antagonist domperidone (5 mg/kg i.p. ) (haloperidol+ domperidone) (ii), or prostaglandin synthesis inhibitor indomethacin (10 mg/kg s.c. ) (haloperidol+ indomethacin) (iii) did not aggravate this lesion. (i) In haloperidol+saline challenged mice the lesions were inhibited by co-administration (/kg i.p.) of a gastric pentadecapeptide BPC 157, GlyGluProProProGlyLysProAlaAspAspAlaGlyLeuVal, M.W. 1419 (10 mug, 10 ng, 10 pg, but not 1 pg, 100 fg, 10 fg), bromocriptine (10 mg), omeprazole (10 mg, 100 mg, but not 1 mg). Atropine (10, 100,200 mg), pirenzepine (10, 100,200 mug),misoprostol (10, 100, 200 mug), pantoprazole (1, 10, 100 mg), lansoprazole (0.1, 1, 10 mg), cimetidine (10, 100, 200 mg) and ranitidine (10,100, 200 mg) were not effective. (ii) Dopamine peripheral blockade influence: in haloperidol+domperidone mice, previously effective bromocriptine, pentadecapeptide BPC 157 (10 mug) or omeprazole (10 mg) did not attenuate stomach lesions. (iii) Prostaglandins synthesis blockade effect: in haloperidol+indomethacin mice, previously effective agents, bromocriptine or omeprazole were not active, while BPC 157 effect was only lessened. (C) 2001 Elsevier Science Inc. All rights reserved.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 02/07/20 alle ore 22:12:46